Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled clinical trial at three sites to determine the safety and
preliminary efficacy of the study drug to treat severe head trauma (GCS 4-8). It is
hypothesized that the drug may lower pressure in the brain, reduce mortality and the patient
may have improved neurological function following treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abela Pharmaceuticals, Inc.
Collaborators:
Dr. Mahajan's Hospital & Industrial Trauma Centre Ohio State University University of California, Irvine